Graves' Ophthalmopathy (Ophthalmology) - Drugs in Development, 2021

December 2021 | 117 pages | ID: G4E73E736A31EN
Global Markets Direct

Abstracts

Graves' Ophthalmopathy (Ophthalmology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy – Drugs In Development, 2021, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves ‘ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Graves' Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Graves' Ophthalmopathy (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Graves' Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Graves' Ophthalmopathy - Overview
Graves' Ophthalmopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Graves' Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves' Ophthalmopathy - Companies Involved in Therapeutics Development
Graves' Ophthalmopathy - Drug Profiles
Graves' Ophthalmopathy - Dormant Projects
Graves' Ophthalmopathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Graves' Ophthalmopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Graves' Ophthalmopathy - Pipeline by advanceCor GmbH, 2021
Graves' Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, 2021
Graves' Ophthalmopathy - Pipeline by Genmab AS, 2021
Graves' Ophthalmopathy - Pipeline by GlaxoSmithKline Plc, 2021
Graves' Ophthalmopathy - Pipeline by HanAll Biopharma Co Ltd, 2021
Graves' Ophthalmopathy - Pipeline by ImmunoGen Inc, 2021
Graves' Ophthalmopathy - Pipeline by Novartis AG, 2021
Graves' Ophthalmopathy - Pipeline by Pierre Fabre Pharmaceuticals Inc, 2021
Graves' Ophthalmopathy - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Graves' Ophthalmopathy - Pipeline by Viridian Therapeutics Inc, 2021
Graves' Ophthalmopathy - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Graves' Ophthalmopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021